Pfizer-BioNTech vaccine deliveries could start by the middle of December

Pfizer-BioNTech vaccine deliveries could start by the middle of December

Pfizer and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said.

“The U.S. Food and Drug Administration could grant emergency-use by the middle of December,” BioNTech Chief Executive Ugur Sahin told Reuters TV.

“If all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively,” he said.

The final trial analysis comes a week after initial results showed the vaccine was more than 90% effective.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

multimedia

news